Literature DB >> 17105508

British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006).

B Gazzard1, A J Bernard, M Boffito, D Churchill, S Edwards, N Fisher, A M Geretti, M Johnson, C Leen, B Peters, A Pozniak, J Ross, J Walsh, E Wilkins, M Youle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17105508     DOI： 10.1111/j.1468-1293.2006.00424.x

Source DB:  PubMed          Journal:  HIV Med        ISSN： 1464-2662            Impact factor:   3.180


× No keyword cloud information.
  47 in total

Review 1.  A review of economic evaluations of darunavir boosted by low-dose ritonavir in treatment-experienced persons living with HIV infection.

Authors:  Josephine Mauskopf; Lieven Annemans; Andrew M Hill; Erik Smets
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 2.  The impact of disease stage on direct medical costs of HIV management: a review of the international literature.

Authors:  Adrian Levy; Karissa Johnston; Lieven Annemans; Andrea Tramarin; Julio Montaner
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

3.  US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.

Authors:  Anita Brogan; Josephine Mauskopf; Sandra E Talbird; Erik Smets
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

4.  Modelling the budget impact of darunavir in the treatment of highly treatment-experienced, HIV-infected adults in France.

Authors:  Xavier Colin; Antoine Lafuma; Dominique Costagliola; Erik Smets; Josephine Mauskopf; Pascal Guillon
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

5.  Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.

Authors:  Karen Moeremans; Lieven Annemans; Mickael Löthgren; Gabriele Allegri; Veronique Wyffels; Lindsay Hemmet; Karin Caekelbergh; Erik Smets
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

6.  Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: evidence from POWER.

Authors:  Andrew M Hill; Kelly Gebo; Lindsay Hemmett; Mickael Löthgren; Gabriele Allegri; Erik Smets
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

7.  Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.

Authors:  Karen Moeremans; Lindsay Hemmett; Jonas Hjelmgren; Gabriele Allegri; Erik Smets
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

8.  Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.

Authors:  Josephine Mauskopf; Anita Brogan; Silas Martin; Erik Smets
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

9.  HIV.

Authors:  E J Smit
Journal:  Sex Transm Infect       Date:  2006-12       Impact factor: 3.519

10.  Characterization of rodent models of HIV-gp120 and anti-retroviral-associated neuropathic pain.

Authors:  Victoria C J Wallace; Julie Blackbeard; Andrew R Segerdahl; Fauzia Hasnie; Timothy Pheby; Stephen B McMahon; Andrew S C Rice
Journal:  Brain       Date:  2007-08-30       Impact factor: 13.501
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.